Your browser doesn't support javascript.
loading
Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide.
Meltzer, L T; Serpa, K A; Moos, W H.
Affiliation
  • Meltzer LT; Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105.
Psychopharmacology (Berl) ; 99(1): 103-8, 1989.
Article in En | MEDLINE | ID: mdl-2506595
ABSTRACT
Muramyl dipeptide increased sleep during the dark-phase, but not the light-phase of the rats' sleep-awake cycle. This circadian variation may be due to the inability of MDP to increase sleep over the high baseline levels of sleep that occur during the light-phase. However, MDP was pyrogenic during the light-phase, indicating it was pharmacologically active. In the dark-phase, MDP was not pyrogenic, but when compared to concurrent vehicle-treated rats, rats treated with MDP did not demonstrate as great a fall in body temperature. At approximately equisomnogenic doses, MDP produced less potentiation of ethanol-induced loss of righting reflex than triazolam, indicating it produces less non-specific central nervous system depressant effects. These data indicate the possibility of a new generation of hypnotic agents derived from muramyl peptides.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Sleep / Body Temperature / Central Nervous System Depressants / Acetylmuramyl-Alanyl-Isoglutamine Limits: Animals Language: En Journal: Psychopharmacology (Berl) Year: 1989 Document type: Article
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Sleep / Body Temperature / Central Nervous System Depressants / Acetylmuramyl-Alanyl-Isoglutamine Limits: Animals Language: En Journal: Psychopharmacology (Berl) Year: 1989 Document type: Article